Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Free Cash Flow (2016 - 2025)

PAVmed has reported Free Cash Flow over the past 5 years, most recently at -$1.5 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 1788.89% year-over-year to -$1.5 million; the TTM value through Dec 2025 reached -$5.2 million, up 78.81%, while the annual FY2025 figure was -$5.2 million, 84.42% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$1.5 million at PAVmed, down from -$903000.0 in the prior quarter.
  • Over five years, Free Cash Flow peaked at $90000.0 in Q4 2024 and troughed at -$22.9 million in Q2 2022.
  • A 5-year average of -$10.4 million and a median of -$11.7 million in 2024 define the central range for Free Cash Flow.
  • Biggest five-year swings in Free Cash Flow: soared 100.75% in 2024 and later tumbled 1788.89% in 2025.
  • Year by year, Free Cash Flow stood at -$18.1 million in 2021, then increased by 5.17% to -$17.1 million in 2022, then increased by 29.58% to -$12.1 million in 2023, then soared by 100.75% to $90000.0 in 2024, then tumbled by 1788.89% to -$1.5 million in 2025.
  • Business Quant data shows Free Cash Flow for PAVM at -$1.5 million in Q4 2025, -$903000.0 in Q3 2025, and -$1.2 million in Q2 2025.